Start Over

Intracellular delivery of serum-derived hepatitis C virus.

Authors :: Fukuhara T
Tani H
Shiokawa M
Goto Y
Abe T
Taketomi A
Shirabe K
Maehara Y
Matsuura Y
Source :: Microbes and infection [Microbes Infect] 2011 Apr; Vol. 13 (4), pp. 405-12. Date of Electronic Publication: 2011 Jan 22.
Publication Year :: 2011
Abstract: A robust and reliable cell culture system for serum-derived HCV (HCVser) has not been established yet because of the presence of neutralizing antibody and tropism for infection. To overcome this obstacle, we employed a lipid-mediated protein intracellular delivery reagent (PIDR) that permits internalization of proteins into cells. Although entry of HCVcc was not enhanced by the treatment with PIDR, entry of HCVser into hepatoma cell lines (Huh7 and HepG2) and immortalized primary hepatocytes (Hc and HuS/E2) was significantly enhanced by the PIDR treatment. The entry of HCVser into Huh7 cells in the presence of PIDR was resistant to the neutralization by an anti-hCD81 antibody, suggesting that PIDR is capable of internalizing HCVser in a receptor-independent manner. Interestingly, the PIDR-mediated entry of HCVser and HCVcc was enhanced by the addition of sera from chronic hepatitis C patients but not from healthy donors. In addition, neutralization of HCVcc infection by anti-E2 antibody was canceled by the treatment with PIDR. In conclusion, the PIDR is a valuable tool to get over the obstacle of neutralizing antibodies to internalize HCV into cells and might be useful for the establishment of in vitro propagation HCVser.<br /> (Copyright © 2011 Institut Pasteur. Published by Elsevier SAS. All rights reserved.)